The present invention relates to new crystalline forms of vilanteroltrifenatate, processes for their preparation, and theiruse in a pharmaceutical composition for the treatment of respiratory diseases,particularly for the treatment of asthma and chronicobstructive pulmonary disease. In particular, the present invention relates toa crystalline form of vilanterol trifenatate characterised inthat the form has an XRPD pattern as defined herein having characteristicdiffraction angles (2-theta or 2.THETA. (°)) falling within or at eachend of one or more of the following ranges: (a) 3 to 5°, such as 3.8 to4.4°； and/or (b) 7 to 9.9°, such as 7 to 8.5°； and/or (c)12 to 13.3°,such as 12 to 13.3°； and/or (d) 16.4 to 17.3°, such as 16.4 to17.3°； and/or (e)26.8 to 28.3°, such as 26.8 to 28.3°
